TOP TEN perturbations for 38452_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38452_at
Selected probe(set): 212129_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38452_at (212129_at) across 6674 perturbations tested by GENEVESTIGATOR:
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-3.4519958Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
ELK1 depletion study 1 (siRNA) / control siRNA transfected MCF10A cell sample
Relative Expression (log2-ratio):-1.9465609Number of Samples:3 / 3
| Experimental | ELK1 depletion study 1 (siRNA) |
| MCF10A cell line transfected with 20 nM targeting ELK1 for 48 hours. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours. | |
| Control | control siRNA transfected MCF10A cell sample |
| MCF10A cell line transfected with 20 nM control siRNA (siGAPDH) for 48 hours. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours. |
ELK1 depletion study 1 (siRNA; EGF) / control siRNA transfected MCF10A cell sample
Relative Expression (log2-ratio):-1.7920732Number of Samples:3 / 3
| Experimental | ELK1 depletion study 1 (siRNA; EGF) |
| MCF10A cell line transfected with 20 nM targeting ELK1 for 48 hours. Cells were then stimulated with complete media containing 20 ng/ml EGF for 30 minutes. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours. ATC code:--- | |
| Control | control siRNA transfected MCF10A cell sample |
| MCF10A cell line transfected with 20 nM control siRNA (siGAPDH) for 48 hours. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours. |
ELK1 depletion study 1 (siRNA; EGF) / control siRNA transfected MCF10A cell sample (EGF)
Relative Expression (log2-ratio):-1.736351Number of Samples:3 / 3
| Experimental | ELK1 depletion study 1 (siRNA; EGF) |
| MCF10A cell line transfected with 20 nM targeting ELK1 for 48 hours. Cells were then stimulated with complete media containing 20 ng/ml EGF for 30 minutes. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours. ATC code:--- | |
| Control | control siRNA transfected MCF10A cell sample (EGF) |
| MCF10A cell line transfected with 20 nM control siRNA (siGAPDH) for 48 hours. Cells were then stimulated with complete media containing 20 ng/ml EGF for 30 minutes. MCF10A cells were plated out into a mixture of 83% growth medium (DMEM/F12 containing 5% horse serum, 10 mg/ml insulin, 100 ng/ml cholera toxin and 0.5 mg/ml hydrocortisone), 17% OptiMEM (Invitrogen), 20 nM siRNA and 0.33% Lipofectamine2000 followed by replacement of the transfection mix with appropriate growth media after 12 hours. |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):1.6554127Number of Samples:2 / 2
| Experimental | T-cell activation study 4 |
| T-cell samples antiCD3 activated for 30hrs. | |
| Control | normal resting T-cell sample |
| T cells resting for 30h. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):-1.5740175Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
oncolytic herpes simplex virus study 1 / mock infected peripheral nerve sheath tumor (90-8) cell sample
Relative Expression (log2-ratio):-1.530015Number of Samples:2 / 2
| Experimental | oncolytic herpes simplex virus study 1 |
| Human malignant peripheral nerve sheath tumor (90-8) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (90-8) cell sample |
| Human malignant peripheral nerve sheath tumor (90-8) cells mock infected for 6 hours. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):1.4641294Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
DLBCL study 1 (germinal center B-cell like; unclassified) / DLBCL study 1 (activated B-cell like; unclassified)
Relative Expression (log2-ratio):-1.3937721Number of Samples:2 / 11
| Experimental | DLBCL study 1 (germinal center B-cell like; unclassified) |
| Unclassified B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (germinal center B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS). | |
| Control | DLBCL study 1 (activated B-cell like; unclassified) |
| Unclassified B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS). |
precursor-B-ALL study 2 (E2A-PBX1) / T-ALL study 2
Relative Expression (log2-ratio):1.3758812Number of Samples:2 / 13
| Experimental | precursor-B-ALL study 2 (E2A-PBX1) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
| Control | T-ALL study 2 |
| Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG). |